Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 25Gastrointestinal 22CNS 21Dermatologic 13Breast 10Other solid neoplasm 7Tumor-Agnostic 5Sarcoma 5Head & Neck 4Other hematologic neoplasm 3Lymphoid 3Endocrine 3Myeloid 2Genitourinary 2Plasma cell 1Gynecologic 1

Conditions

Multiple Myeloma 1

Interventions

Dexamethasone 871Bortezomib 457Lenalidomide 456Cyclophosphamide 365Melphalan 272Calcium Dobesilate 263daratumumab 234pomalidomide 208carfilzomib 182fludarabine phosphate 140fludarabine 136Thalidomide 125Peripheral Blood Stem Cell Transplantation 119Filgrastim 114ixazomib 93Mycophenolic Acid 90Granulocyte Colony-Stimulating Factor 89Whole-Body Irradiation 87Busulfan 87dexamethasone acetate 86Tacrolimus 78dexamethasone 21-phosphate 74isatuximab 69Cyclosporine 68auricularum 67Prednisone 65elotuzumab 58belantamab mafodotin 57Antilymphocyte Serum 56Etoposide 53

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × AZD 6244 × Plasma cell × Clear all
NCT01085214 2015-08-19

AZD6244 (Selumetinib) in Treating Patients With Multiple Myeloma

National Cancer Institute (NCI)

Phase 2 Completed
37 enrolled 9 charts
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡